ArticleJournal of molecular medicine (Berlin, Germany)2025
MicroRNA-100-5p in exosomes from human placental mesenchymal stem cells: a key modulator of anti-psoriatic effects through mTOR/S6 K1 pathway.
Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Exosomes in Psoriasis: From Pathogenic Mechanisms to Therapeutic Innovations.Clinical, cosmetic and investigational dermatology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Exosomes from mesenchymal stem cells (MSCs) demonstrate therapeutic potential against psoriasis, primarily due to their anti-inflammatory properties. However, the specific components within the exosomal cargo, particularly microRNAs, that mediate this activity remain unclear. This study investigated the role of a specific microRNA in mediating the therapeutic effects of exosomes from human placenta MSCs (MSC-exosomes) in an imiquimod (IMQ)-induced psoriasis murine model, with a focus on the underlying mechanisms, particularly the downstream pathways of the specific microRNA. Our small RNA sequencing analysis identified microRNA (miR)-100-5p as a potential target. Adult male Balb/c mice were then randomly assigned to the IMQ, IMQ plus MSC-exosomes (IMQ + Exo), IMQ plus MSC-exosomes treated with a specific miR-100-5p inhibitor (IMQ + Exoi), or IMQ plus agomiR-100-5p group (IMQ + AgomiR) (n = 6 per group). Control groups were also included. Mice were sacrificed, and psoriasis severity was assessed the day after 6 consecutive days of daily IMQ exposure, followed by 7 consecutive days of daily treatment. The IMQ + Exo group exhibited significantly lower epidermal thickness, levels of inflammatory cytokines and psoriasis-related cytokines (interleukin [IL]-12, IL-17, and IL-23), and expression of mammalian target of rapamycin (mTOR)/S6 kinase 1 (S6K1) (the predicted downstream target of miR-100-5p), compared to the IMQ group (all p < 0.05). Notably, inhibition of miR-100-5p nullified these therapeutic effects of MSC-exosomes. This study provides evidence that miR-100-5p plays a crucial role in mediating the therapeutic effects of MSC-exosomes in an IMQ-induced murine psoriasis model, potentially by modulating the mTOR/S6K1 pathway. KEY MESSAGES: • Exosomes from human placental mesenchymal stem sells demonstrate therapeutic potential against psoriasis. • MicroRNA-100-5p plays a crucial role in mediating the therapeutic effects of mesenchymal stem cells exosomes in an imiquimod-induced murine psoriasis model, potentially by modulating the mammalian target of rapamycin/S6 kinase 1 pathway.
Indexed as
Identifiers
40483360What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.